APO Research
Talk to an analyst

APO RESEARCH · REPORT

Complement C5 Recombinant Monoclonal Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Complement C5 Recombinant Monoclonal Antibody Market Outlook and Growth Opportunities 2026

29 December 2025198 pages

Choose your research edition.

Industry ResearchComplement C5 Recombinant Monoclonal Antibody Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Complement C5 Recombinant Monoclonal Antibody Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Complement C5 Recombinant Monoclonal Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Complement C5 Recombinant Monoclonal Antibody Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Complement C5 Recombinant Monoclonal Antibody Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Complement C5 Recombinant Monoclonal Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Complement C5 Recombinant Monoclonal Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Complement C5 Recombinant Monoclonal Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Complement C5 Recombinant Monoclonal Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Complement C5 Recombinant Monoclonal Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Complement C5 Recombinant Monoclonal Antibody market include Alexion Pharmaceuticals, Regeneron Pharmaceuticals, Amgen, Roche and Samsung Bioepis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Complement C5 Recombinant Monoclonal Antibody market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Complement C5 Recombinant Monoclonal Antibody and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Complement C5 Recombinant Monoclonal Antibody sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Complement C5 Recombinant Monoclonal Antibody market size, projected growth trends, production technologies, key applications, and end-use industries.

Complement C5 Recombinant Monoclonal Antibody Segment by Company

Alexion Pharmaceuticals

Regeneron Pharmaceuticals

Amgen

Roche

Samsung Bioepis

Complement C5 Recombinant Monoclonal Antibody Segment by Type

Eculizumab

Pozelimab

Ravulizumab

Crovalimab

Others

Complement C5 Recombinant Monoclonal Antibody Segment by Application

PNH

CD55 Deficiency

aHUS

Others

Complement C5 Recombinant Monoclonal Antibody Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Complement C5 Recombinant Monoclonal Antibody status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Complement C5 Recombinant Monoclonal Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Complement C5 Recombinant Monoclonal Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze Complement C5 Recombinant Monoclonal Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Complement C5 Recombinant Monoclonal Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Complement C5 Recombinant Monoclonal Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Complement C5 Recombinant Monoclonal Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Complement C5 Recombinant Monoclonal Antibody market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Complement C5 Recombinant Monoclonal Antibody industry.

Chapter 3: Detailed analysis of Complement C5 Recombinant Monoclonal Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Complement C5 Recombinant Monoclonal Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Complement C5 Recombinant Monoclonal Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Complement C5 Recombinant Monoclonal Antibody Industry Trends Table 2. Complement C5 Recombinant Monoclonal Antibody Industry Drivers Table 3. Complement C5 Recombinant Monoclonal Antibody Industry Opportunities and Challenges Table 4. Complement C5 Recombinant Monoclonal Antibody Industry Restraints Table 5. Global Complement C5 Recombinant Monoclonal Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Complement C5 Recombinant Monoclonal Antibody Revenue Share by Company (2021-2026) Table 7. Global Complement C5 Recombinant Monoclonal Antibody Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Complement C5 Recombinant Monoclonal Antibody Sales Volume Share by Company (2021-2026) Table 9. Global Complement C5 Recombinant Monoclonal Antibody Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Complement C5 Recombinant Monoclonal Antibody Company Ranking, (2024-2026) & (USD Million) Table 11. Global Complement C5 Recombinant Monoclonal Antibody Key Company Manufacturing Base & Headquarters Table 12. Global Complement C5 Recombinant Monoclonal Antibody Company, Product Type & Application Table 13. Global Complement C5 Recombinant Monoclonal Antibody Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Complement C5 Recombinant Monoclonal Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Eculizumab Table 18. Significant Companies of Pozelimab Table 19. Significant Companies of Ravulizumab Table 20. Significant Companies of Crovalimab Table 21. Significant Companies of Others Table 22. Global Complement C5 Recombinant Monoclonal Antibody Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Complement C5 Recombinant Monoclonal Antibody Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Complement C5 Recombinant Monoclonal Antibody Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Complement C5 Recombinant Monoclonal Antibody Sales Volume Share by Type (2021-2026) Table 26. Global Complement C5 Recombinant Monoclonal Antibody Sales Volume Share by Type (2027-2032) Table 27. Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type (2021-2026) Table 31. Global Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type (2027-2032) Table 32. Significant Companies of PNH Table 33. Significant Companies of CD55 Deficiency Table 34. Significant Companies of aHUS Table 35. Significant Companies of Others Table 36. Global Complement C5 Recombinant Monoclonal Antibody Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Complement C5 Recombinant Monoclonal Antibody Sales Volume by Application (2021-2026) & (K Units) Table 38. Global Complement C5 Recombinant Monoclonal Antibody Sales Volume by Application (2027-2032) & (K Units) Table 39. Global Complement C5 Recombinant Monoclonal Antibody Sales Volume Share by Application (2021-2026) Table 40. Global Complement C5 Recombinant Monoclonal Antibody Sales Volume Share by Application (2027-2032) Table 41. Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application (2021-2026) Table 45. Global Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application (2027-2032) Table 46. Global Complement C5 Recombinant Monoclonal Antibody Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Complement C5 Recombinant Monoclonal Antibody Sales by Region (2021-2026) & (K Units) Table 48. Global Complement C5 Recombinant Monoclonal Antibody Sales Market Share by Region (2021-2026) Table 49. Global Complement C5 Recombinant Monoclonal Antibody Sales by Region (2027-2032) & (K Units) Table 50. Global Complement C5 Recombinant Monoclonal Antibody Sales Market Share by Region (2027-2032) Table 51. Global Complement C5 Recombinant Monoclonal Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Region (2021-2026) Table 54. Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Region (2027-2032) Table 56. Global Complement C5 Recombinant Monoclonal Antibody Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Complement C5 Recombinant Monoclonal Antibody Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Complement C5 Recombinant Monoclonal Antibody Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Complement C5 Recombinant Monoclonal Antibody Sales by Country (2021-2026) & (K Units) Table 61. Global Complement C5 Recombinant Monoclonal Antibody Sales Market Share by Country (2021-2026) Table 62. Global Complement C5 Recombinant Monoclonal Antibody Sales by Country (2027-2032) & (K Units) Table 63. Global Complement C5 Recombinant Monoclonal Antibody Sales Market Share by Country (2027-2032) Table 64. Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Complement C5 Recombinant Monoclonal Antibody Sales Value Market Share by Country (2021-2026) Table 66. Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Complement C5 Recombinant Monoclonal Antibody Sales Value Market Share by Country (2027-2032) Table 68. Alexion Pharmaceuticals Company Information Table 69. Alexion Pharmaceuticals Business Overview Table 70. Alexion Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Alexion Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody Product Portfolio Table 72. Alexion Pharmaceuticals Recent Development Table 73. Regeneron Pharmaceuticals Company Information Table 74. Regeneron Pharmaceuticals Business Overview Table 75. Regeneron Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Regeneron Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody Product Portfolio Table 77. Regeneron Pharmaceuticals Recent Development Table 78. Amgen Company Information Table 79. Amgen Business Overview Table 80. Amgen Complement C5 Recombinant Monoclonal Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Amgen Complement C5 Recombinant Monoclonal Antibody Product Portfolio Table 82. Amgen Recent Development Table 83. Roche Company Information Table 84. Roche Business Overview Table 85. Roche Complement C5 Recombinant Monoclonal Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Roche Complement C5 Recombinant Monoclonal Antibody Product Portfolio Table 87. Roche Recent Development Table 88. Samsung Bioepis Company Information Table 89. Samsung Bioepis Business Overview Table 90. Samsung Bioepis Complement C5 Recombinant Monoclonal Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Samsung Bioepis Complement C5 Recombinant Monoclonal Antibody Product Portfolio Table 92. Samsung Bioepis Recent Development Table 93. Key Raw Materials Table 94. Raw Materials Key Suppliers Table 95. Complement C5 Recombinant Monoclonal Antibody Distributors List Table 96. Complement C5 Recombinant Monoclonal Antibody Customers List Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Complement C5 Recombinant Monoclonal Antibody Product Image Figure 2. Global Complement C5 Recombinant Monoclonal Antibody Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Complement C5 Recombinant Monoclonal Antibody Sales Value (2021-2032) & (US$ Million) Figure 4. Global Complement C5 Recombinant Monoclonal Antibody Sales (2021-2032) & (K Units) Figure 5. Global Complement C5 Recombinant Monoclonal Antibody Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Complement C5 Recombinant Monoclonal Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Eculizumab Image Figure 10. Pozelimab Image Figure 11. Ravulizumab Image Figure 12. Crovalimab Image Figure 13. Others Image Figure 14. Global Complement C5 Recombinant Monoclonal Antibody Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Complement C5 Recombinant Monoclonal Antibody Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Complement C5 Recombinant Monoclonal Antibody Sales Volume Share by Type (2021-2032) Figure 17. Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Complement C5 Recombinant Monoclonal Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type (2021-2032) Figure 20. PNH Image Figure 21. CD55 Deficiency Image Figure 22. aHUS Image Figure 23. Others Image Figure 24. Global Complement C5 Recombinant Monoclonal Antibody Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Complement C5 Recombinant Monoclonal Antibody Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Complement C5 Recombinant Monoclonal Antibody Sales Volume Share by Application (2021-2032) Figure 27. Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Complement C5 Recombinant Monoclonal Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application (2021-2032) Figure 30. Global Complement C5 Recombinant Monoclonal Antibody Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global Complement C5 Recombinant Monoclonal Antibody Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Complement C5 Recombinant Monoclonal Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Complement C5 Recombinant Monoclonal Antibody Sales Value (2021-2032) & (US$ Million) Figure 35. North America Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Complement C5 Recombinant Monoclonal Antibody Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Complement C5 Recombinant Monoclonal Antibody Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Complement C5 Recombinant Monoclonal Antibody Sales Value (2021-2032) & (US$ Million) Figure 41. South America Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Complement C5 Recombinant Monoclonal Antibody Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Complement C5 Recombinant Monoclonal Antibody Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Complement C5 Recombinant Monoclonal Antibody Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Eculizumab
  • Pozelimab
  • Ravulizumab
  • Crovalimab
  • Others
Applications
  • PNH
  • CD55 Deficiency
  • aHUS
  • Others
Companies covered
  • Alexion Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Amgen
  • Roche
  • Samsung Bioepis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Complement C5 Recombinant Monoclonal Antibody Sales Value (2021-2032)
  4. 1.2.2 Global Complement C5 Recombinant Monoclonal Antibody Sales Volume (2021-2032)
  5. 1.2.3 Global Complement C5 Recombinant Monoclonal Antibody Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Complement C5 Recombinant Monoclonal Antibody Market Dynamics
  1. 2.1 Complement C5 Recombinant Monoclonal Antibody Industry Trends
  2. 2.2 Complement C5 Recombinant Monoclonal Antibody Industry Drivers
  3. 2.3 Complement C5 Recombinant Monoclonal Antibody Industry Opportunities and Challenges
  4. 2.4 Complement C5 Recombinant Monoclonal Antibody Industry Restraints
3 Complement C5 Recombinant Monoclonal Antibody Market by Company
  1. 3.1 Global Complement C5 Recombinant Monoclonal Antibody Company Revenue Ranking in 2025
  2. 3.2 Global Complement C5 Recombinant Monoclonal Antibody Revenue by Company (2021-2026)
  3. 3.3 Global Complement C5 Recombinant Monoclonal Antibody Sales Volume by Company (2021-2026)
  4. 3.4 Global Complement C5 Recombinant Monoclonal Antibody Average Price by Company (2021-2026)
  5. 3.5 Global Complement C5 Recombinant Monoclonal Antibody Company Ranking (2024-2026)
  6. 3.6 Global Complement C5 Recombinant Monoclonal Antibody Company Manufacturing Base and Headquarters
  7. 3.7 Global Complement C5 Recombinant Monoclonal Antibody Company Product Type and Application
  8. 3.8 Global Complement C5 Recombinant Monoclonal Antibody Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Complement C5 Recombinant Monoclonal Antibody Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Complement C5 Recombinant Monoclonal Antibody Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Complement C5 Recombinant Monoclonal Antibody Market by Type
  1. 4.1 Complement C5 Recombinant Monoclonal Antibody Type Introduction
  2. 4.1.1 Eculizumab
  3. 4.1.2 Pozelimab
  4. 4.1.3 Ravulizumab
  5. 4.1.4 Crovalimab
  6. 4.1.5 Others
  7. 4.2 Global Complement C5 Recombinant Monoclonal Antibody Sales Volume by Type
  8. 4.2.1 Global Complement C5 Recombinant Monoclonal Antibody Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Complement C5 Recombinant Monoclonal Antibody Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Complement C5 Recombinant Monoclonal Antibody Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Type
  12. 4.3.1 Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Type (2021-2032)
  14. 4.3.3 Global Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type (2021-2032)
5 Complement C5 Recombinant Monoclonal Antibody Market by Application
  1. 5.1 Complement C5 Recombinant Monoclonal Antibody Application Introduction
  2. 5.1.1 PNH
  3. 5.1.2 CD55 Deficiency
  4. 5.1.3 aHUS
  5. 5.1.4 Others
  6. 5.2 Global Complement C5 Recombinant Monoclonal Antibody Sales Volume by Application
  7. 5.2.1 Global Complement C5 Recombinant Monoclonal Antibody Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Complement C5 Recombinant Monoclonal Antibody Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Complement C5 Recombinant Monoclonal Antibody Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Application
  11. 5.3.1 Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Application (2021-2032)
  13. 5.3.3 Global Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application (2021-2032)
6 Complement C5 Recombinant Monoclonal Antibody Regional Sales and Value Analysis
  1. 6.1 Global Complement C5 Recombinant Monoclonal Antibody Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Complement C5 Recombinant Monoclonal Antibody Sales by Region (2021-2032)
  3. 6.2.1 Global Complement C5 Recombinant Monoclonal Antibody Sales by Region: 2021-2026
  4. 6.2.2 Global Complement C5 Recombinant Monoclonal Antibody Sales by Region (2027-2032)
  5. 6.3 Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Region (2021-2032)
  7. 6.4.1 Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Region: 2021-2026
  8. 6.4.2 Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Region (2027-2032)
  9. 6.5 Global Complement C5 Recombinant Monoclonal Antibody Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Complement C5 Recombinant Monoclonal Antibody Sales Value (2021-2032)
  12. 6.6.2 North America Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Complement C5 Recombinant Monoclonal Antibody Sales Value (2021-2032)
  15. 6.7.2 Europe Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Complement C5 Recombinant Monoclonal Antibody Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Complement C5 Recombinant Monoclonal Antibody Sales Value (2021-2032)
  21. 6.9.2 South America Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Complement C5 Recombinant Monoclonal Antibody Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Country, 2025 VS 2032
7 Complement C5 Recombinant Monoclonal Antibody Country-level Sales and Value Analysis
  1. 7.1 Global Complement C5 Recombinant Monoclonal Antibody Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Complement C5 Recombinant Monoclonal Antibody Sales by Country (2021-2032)
  4. 7.3.1 Global Complement C5 Recombinant Monoclonal Antibody Sales by Country (2021-2026)
  5. 7.3.2 Global Complement C5 Recombinant Monoclonal Antibody Sales by Country (2027-2032)
  6. 7.4 Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Country (2021-2032)
  7. 7.4.1 Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Country (2021-2026)
  8. 7.4.2 Global Complement C5 Recombinant Monoclonal Antibody Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Complement C5 Recombinant Monoclonal Antibody Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Complement C5 Recombinant Monoclonal Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Alexion Pharmaceuticals
  2. 8.1.1 Alexion Pharmaceuticals Company Information
  3. 8.1.2 Alexion Pharmaceuticals Business Overview
  4. 8.1.3 Alexion Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Alexion Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody Product Portfolio
  6. 8.1.5 Alexion Pharmaceuticals Recent Developments
  7. 8.2 Regeneron Pharmaceuticals
  8. 8.2.1 Regeneron Pharmaceuticals Company Information
  9. 8.2.2 Regeneron Pharmaceuticals Business Overview
  10. 8.2.3 Regeneron Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Regeneron Pharmaceuticals Complement C5 Recombinant Monoclonal Antibody Product Portfolio
  12. 8.2.5 Regeneron Pharmaceuticals Recent Developments
  13. 8.3 Amgen
  14. 8.3.1 Amgen Company Information
  15. 8.3.2 Amgen Business Overview
  16. 8.3.3 Amgen Complement C5 Recombinant Monoclonal Antibody Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Complement C5 Recombinant Monoclonal Antibody Product Portfolio
  18. 8.3.5 Amgen Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Complement C5 Recombinant Monoclonal Antibody Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Roche Complement C5 Recombinant Monoclonal Antibody Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Samsung Bioepis
  26. 8.5.1 Samsung Bioepis Company Information
  27. 8.5.2 Samsung Bioepis Business Overview
  28. 8.5.3 Samsung Bioepis Complement C5 Recombinant Monoclonal Antibody Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Samsung Bioepis Complement C5 Recombinant Monoclonal Antibody Product Portfolio
  30. 8.5.5 Samsung Bioepis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Complement C5 Recombinant Monoclonal Antibody Value Chain Analysis
  2. 9.1.1 Complement C5 Recombinant Monoclonal Antibody Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Complement C5 Recombinant Monoclonal Antibody Sales Mode & Process
  6. 9.2 Complement C5 Recombinant Monoclonal Antibody Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Complement C5 Recombinant Monoclonal Antibody Distributors
  9. 9.2.3 Complement C5 Recombinant Monoclonal Antibody Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst